Recombinant Mouse LRIG1 Protein (His Tag) | PKSM041310

Recombinant Mouse LRIG1 Protein (His Tag) | PKSM041310 | Gentaur US, UK & Europe Disrtribition

Synonyms: Leucine-rich repeats and immunoglobulin-like domains protein 1; LIG-1; Lrig1

Active Protein: N/A

Activity: Recombinant Mouse LRIG1 is produced by our Mammalian expression system and the target gene encoding Ala35-Thr794 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Mouse LRIG1 is produced by our Mammalian expression system and the target gene encoding Ala35-Thr794 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-His

Species: Mouse

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 84.5 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: LRIG1 is a leucine-rich repeat (LRR) and Ig-like domain-containing single-pass transmembrane glycoprotein. LRIG1 shares 45-50% aa identity with its mammalian paralogs, LRIG2 and LRIG3. LIRG1 is expressed widely throughout mouse and human tissues, including the liver, brain, stomach, small intestine, skeletal muscle, cornea, and hair follicle. It has been shown to suppress tumor growth, regulate tissue homeostasis, and maintain stem cell quiescence. The LRIG1 ECD contains three C-type Ig-like domains as well as fifteen LRRs that are flanked by cysteine-rich regions. LRIG1 functions as a tumor suppressor by controlling cell proliferation through the negative regulation of the EGF family of receptor tyrosine kinases. LRIG1 expression, which is often dysregulated in human cancers, is a prognostic indicator of cancer development and relapse? Decreased LRIG1 is associated with an increase in recurrence and mortality for a variety of cancers including breast, uterine, headandneck, glioma, prostate, and squamous cell. Tissue homeostasis and stem cell dormancy is also thought to be modulated by the actions of LRIG1 on cell proliferation.

Research Area: N/A